Principles and Annex 1 were adopted in January 2025. Annex 2, covering decentralized and pragmatic trial elements, followed in June 2026. Here is what actually changed and what to do about it.
Free sandbox · No credit card · 21 CFR Part 11 aligned
Stage 1
DraftBuild and edit freely
Stage 2
ApprovedLocked for live use
Stage 3
In the casebookOnly approved forms
SDV requirement changed on Systolic BP
Data manager · Reason: critical safety value
Form approved: Vital Signs (VS) v2
Study owner · Locked for live use
Answer changed: Weight 68.0 to 68.5 kg
Site coordinator · Reason: transcription error
Jan 2025
Principles and Annex 1 adopted
Jun 2026
Annex 2 adopted: decentralized and pragmatic elements
25+ yrs
since the last GCP revision this size
1
core idea: proportionate, risk-based oversight
The core shift
E6(R2) applied a similar level of prescribed process to most trial activities. E6(R3) asks sponsors to identify the factors genuinely critical to a specific trial's quality, then focus oversight and monitoring effort there instead of spreading it evenly across everything.
protocol_v3.pdf
Draft study
Timeline
ICH guidelines are adopted centrally, then implemented locally on each region's own schedule.
ICH adopts the E6(R3) Principles and Annex 1, covering the core revision to GCP.
FDA releases final guidance aligning US practice with the new principles.
ICH adopts Annex 2, adding guidance for decentralized elements, pragmatic trial designs and real-world data.
Regional regulators adopt and phase in the guideline on their own timelines. Check your relevant authority for the applicable date.
What to actually do
Risk-based does not mean less documentation. It means documented reasoning instead of a blanket checklist.
A short quality plan naming the two or three factors that would actually threaten this trial's results.
Spend more review time on the data points you flagged as critical, less on routine, low-risk fields.
Use a study builder you can amend yourself if you add a decentralized or pragmatic element later.
E6(R3) does not lower the bar on audit trails or data integrity; it changes how oversight effort is allocated.
Draft your visits and forms with AI, then adjust them yourself as your quality plan evolves.
Where Capture fits
Risk-based quality management works best when your systems do not force a one-size-fits-all build. Capture's study builder and AI-drafted CRFs let you scope forms and visits to a specific protocol, and amend them yourself as your risk assessment changes.
Demographics
SDTM DM
Vital signs
SDTM VS
ECG
SDTM EG
Physical examination
SDTM PE
Laboratory
SDTM LB
Medical history
SDTM MH
Adverse events
SDTM AE
Concomitant medications
SDTM CM
The Principles and Annex 1 were adopted in January 2025. Annex 2, covering decentralized and pragmatic trial elements and real-world data, was adopted in June 2026. Local regulators phase in ICH guidelines on their own timelines, so check your relevant authority for the applicable date.
The shift from a largely prescriptive checklist to risk-based, proportionate quality management: sponsors identify what is genuinely critical to a trial's quality and focus oversight there.
No. It expands the guideline to explicitly support decentralized and pragmatic elements when a sponsor chooses to use them. It does not require any specific trial design.
Not less, different. Effort shifts away from uniform oversight of everything and toward the specific factors a sponsor has identified as critical, which needs to be documented, not assumed.
Capture is built to ICH-GCP E6(R2) today. E6(R3) is guidance for how sponsors run and oversee trials rather than a software certification, and we are tracking Annex 2 as it is adopted locally. Contact us for specifics on your quality plan.
Keep exploring
21 CFR Part 11 compliance checklist
The FDA-side regulation running alongside ICH guidance.
ALCOA+ data integrity checklist
The data-integrity principles E6(R3) still assumes.
Clinical trial study builder
A build you can scope and amend yourself.
Decentralized clinical trial software
Support for the trial elements Annex 2 addresses.
Platform overview
EDC, eConsent, ePRO and randomization in one system.
AI in Capture
How AI drafts studies without removing human review.
Free sandbox with every feature. No credit card, no sales call.